Drug Profile
Fordadistrogene movaparvovec - Pfizer
Alternative Names: BMB-D-001; PF 06939926Latest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Bamboo Therapeutics
- Developer Pfizer
- Class Gene therapies
- Mechanism of Action Dystrophin replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Duchenne muscular dystrophy
Most Recent Events
- 14 Nov 2023 US FDA granted Rare Pediatric Disease for Duchenne muscular dystrophy, prior to November 2023 (Pfizer website, November 2023)
- 13 Mar 2023 Pfizer initiates a phase III trial for Duchenne Muscular Dystrophy (In children, In adolescents, In adults, In the elderly) in USA (NCT05689164)
- 19 Jan 2023 Pfizer plans a phase III trial for Duchenne Muscular Dystrophy(In children, In adolescents, In adults, In the elderly) in April 2023(NCT05689164)